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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not are D-
mannose pills an effective form of prophylaxis for women prone to recurrent urinary tract 
infections? 
Study Design: Systematic review of three randomized controlled trials (RCTs) published 
between 2014-2016, all in the English language. 
Data Sources: Three randomized controlled trials (RCTs) which evaluated the effectiveness of 
D-mannose as prophylaxis against recurrent UTI in women as compared to control groups either 
given no prophylaxis and or antibiotic prophylaxis. All studies were found using PubMed and 
the Cochrane library. 
Outcomes Measured: All three studies measured the number of patients that had a recurrent 
UTI during the follow-up period. One study also measured the time to recurrence of UTI and 
change in pain and urgency symptoms on the visual analog scale (VAS).  
Results: All three studies found that patients were significantly less likely to have a UTI 
recurrence with D-mannose compared to no agents for prophylaxis. One study found similar 
efficacy of D-mannose and nitrofurantoin for prophylaxis; however, tolerability of D-mannose 
was significantly better than that of nitrofurantoin. A third study found that D-mannose 
prevented urinary tract infections better than trimethoprim-sulfamethoxazole (TMP-SMX), 
however, dosing of TMP-SMX was suboptimal. 
Conclusions: D-mannose was found to be effective in preventing recurrence of urinary tract 
infections in women prone to such infections. Further studies are needed to determine optimal 
dosing of D-mannose for prophylaxis. In addition, more studies conducting an adequate 
comparison of D-mannose to conventional antimicrobial therapy are required before 
implementing this supplement as standard of care.  
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INTRODUCTION 
A urinary tract infection (UTI) is a bacterial infection of the urinary tract that either 
manifests as cystitis or migrates up the urinary tract into the kidney and causes pyelonephritis. 
UTI is one of the most common infections occurring in females worldwide.1 Recurrent urinary 
tract infection is defined as two culture-proven infections in 6 months or 3 in 12 months.1,2. UTIs 
are most commonly caused by E. coli. Other less common pathogens include S. saprophyticus, 
Klebsiella pneumoniae, and Proteus mirabilis.1 The condition is more common in females due to 
anatomic features allowing easy ascent of fecal flora into the urinary tract. Recurrent urinary tract 
infections can occur from persistence of bacteria after treatment of initial infection either due to 
inadequate treatment, noncompliance, or high organismal counts. Recurrent infections can also 
occur from recolonization of the urinary tract. Some patients may be predisposed to recurrent 
UTI due to structural or functional abnormalities. 
It is estimated that worldwide, nearly 150 million UTIs occur annually.3  The lifetime risk 
of a female getting a UTI is 50%.1 About 36% of women younger than 55 and 53% of women 
over 55 report recurrence in one year.1 Urinary tract infections are projected to cost over $6 
billion annually3 and account for nearly 7 million office visits per year.4 A retrospective analysis 
in Europe estimates a mean annual cost of $270 per patient for a UTI. This cost includes the 
physician visit, diagnosis, and treatment of the condition.5 In addition to economic burden, 
urinary tract infections, especially recurrent infections, are known to cause significant painful 
symptoms and psychological distress in women. 
Uncomplicated UTI is often treated with trimethoprim-sulfamethoxazole (TMP-SMX), 
nitrofurantoin, ciprofloxacin, or cephalexin for 3-10 days depending on the selected therapy and 
the patient. Recurrent UTI is treated with nightly or post-coital prophylaxis with TMP-SMX or 
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nitrofurantoin. With the increasing advent of antibiotic resistance and adverse effects from 
frequent or daily antibiotic use, alternative methods are necessary for preventing recurrent UTI, a 
common, devitalizing condition.  
D-mannose is a simple, natural sugar that inhibits bacterial adhesion to the urothelium.6 
Bacterial fimbriae preferably bind D-mannose in the urine rather than proteins on the bladder 
wall.6 Once bound, this complex is trapped in the urine and eliminated during urination and 
therefore the bacteria cannot cause infection. This mechanism is especially relevant for the most 
common UTI pathogen, E. coli, which exerts its virulence by attaching its fimbriae to the 
urothelium to persist and proliferate in the urinary tract.1 D-mannose has been reported to relieve 
lower urinary tract symptoms and prevent recurrence of UTI in women prone to the condition 
without the use of antimicrobial therapy.6 This paper evaluates 3 randomized, controlled trials 
(RCTs) evaluating the efficacy of D-mannose for prophylaxis against recurrent UTI in females 
prone to this condition compared with no prophylactic therapy and conventional antimicrobials. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not are D-mannose 
pills an effective form of prophylaxis for women prone to recurrent urinary tract infections? 
METHODS 
 This systematic review uses three randomized controlled trials (RCTs). All articles were 
researched using the Cochrane library and PubMed. Articles selected displayed relevance to this 
topic and were required to study outcomes that were POEMs (patient-oriented evidence that 
matters). These articles were found using keywords “D-mannose”, “urinary tract infection”, and 
“women”. All three articles were published in peer-reviewed journals, and all were published in 
English. Articles were published no earlier than 2007. Any studies using male subjects or 
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subjects under age 18 were excluded. See Table 1 for inclusion and exclusion criteria specific to 
each of the studies used in this review.  
Table 1. Demographics and Characteristics of Included Studies 
Study Type # 
pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/
D 
Interventions 
Dome
nici, 
20166 
RCT 45 18-
65 
Women age 18-
65 years, 
symptoms of 
acute cystitis, 
asymptomatic 
with diagnosis 
of a UTI (103 or 
more colony-
forming units 
per mL) 
History of urinary 
tract anomaly, acute 
symptoms >1 week, 
pregnant/breast 
feeding, trying to 
conceive, 
inflammatory UTI, 
hormone replacement, 
interstitial cystitis, 
DM, catheter use, 
previously antibiotic 
prophylaxis, unable to 
fill out questionnaire 
2 D-mannose 1 
week per 
month, every 
other month 
for 6 months 
 
No treatment 
Kranj
cec, 
20142 
RCT 308 29-
58 
Female 
Age > 18 yrs 
Positive history 
of recurrent 
cystitis 
Pregnancy, breast 
feeding, symptoms of 
upper UTI, symptoms 
of inflammatory 
response, history of 
urinary tract 
anomalies, interstitial 
cystitis, DM, use of 
hormone therapy or 
contraception, 
previously had UTI 
prophylaxis 
0 2 g D-
mannose QHS 
 
No 
prophylaxis 
Porru, 
20147 
RCT 60 22-
54 
Female >18 yrs, 
acute 
symptomatic 
UTI, ≥ 3 UTIs 
w. positive 
urine cultures in 
the last 3 
months, no 
antimicrobials 
within 4 weeks, 
not 
pregnant/conte
mplating 
pregnancy 
Upper UTI and/or 
temperature > 38˚ C, 
flank/lumbar pain, 
renal disease, 
anatomic 
abnormalities, prior 
GYN surgery, 
immunosuppressive 
medications or 
diseases 
 
0 D-mannose 3 
g TID x 2 
weeks then 1g 
BID x 22 
weeks 
 
TMP-SMX 
160/800 mg 
BID x 5 days 
then QHS for 
23 weeks 
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The population studied involved women over age 18 with history of recurrent urinary 
tract infection, defined as 3 or more culture-proven urinary tract infections in 12 months. The 
intervention being studied is D-mannose pills for prophylactic therapy against recurrent UTI. 
Comparison in one study was no prophylaxis. The second study had two control groups: one 
given prophylaxis with nitrofurantoin and one given no prophylaxis. The third study used one 
control group given prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX). The major 
outcome measured in these studies was whether or not the patient reported irritative voiding 
symptoms consistent with the onset of an acute, recurrent UTI. Two of the studies confirmed the 
reported infection with a urine culture to verify that symptoms were consistent with a true UTI 
recurrence.  
 Data analysis of this study was conducted using the number of patients in each group 
reporting urinary symptoms after initiation of the prophylactic regimen. One study also recorded 
mean time to recurrence with standard deviation values as well as urinary pain and urgency on 
the visual analog scale (VAS). Statistical analyses used include p-value, risk reduction, and 95% 
confidence intervals. 
OUTCOMES MEASURED 
 The studies measured the number of patients with a recurrence of UTI by patient-reported 
irritative voiding symptoms. These symptoms included dysuria, frequency, urgency, nocturia, 
hematuria, suprapubic pain, and low back pain. Kranjcec et al. and Porru et al. confirmed UTI 
onset with a urine culture after patients reported symptoms. Porru et al. also recorded the mean 
time to recurrence (TTR) of the UTI with standard deviation, and patient-reported pain and 
urinary urgency on the visual analog scale (VAS) with standard deviation.  
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RESULTS 
 Three RCTs were used to determine whether D-mannose is an effective agent for 
prophylaxis against recurrent UTI. Each of the studies compared D-mannose use with no 
prophylactic therapy or other conventional prophylactic methods. Prior to initiation of 
prophylaxis, all studies enrolled patients with acute cystitis; patients were treated as described 
later. In two studies, subjects were considered cured if they reported resolution of symptoms and 
had a negative urine culture. The third study considered patients cured if they did not report 
persistence of symptoms after treatment. The focus of this review is on the follow-up period after 
treatment and cure of acute cystitis when subjects were monitored for recurrence of UTI while 
using D-mannose for prophylaxis or other methods. Refer to Table 2 for comparison of 
recurrence of UTI in women with varying interventions in all RCTs. 
Table 2. Number of patients having a recurrent UTI across all 3 RCTs 
 
Domenici et al. studied women with acute cystitis or asymptomatic culture-proven UTI 
and a history of recurrent UTI. Subjects were treated for acute UTI with D-mannose 1.5 g twice 
per day for 3 days and then once daily for 10 days. Patients were considered cured if they 
Group Number of Patients 
having recurrence of 
UTI 
P-value Numbers needed to 
treat (NNT) 
Domenici et al. 
D-mannose 1 (4.5%) P < 0.05 4 
No prophylaxis 7 (33.3%) 
Krancjec et al. 
D-mannose 15 (14.5%) P < 0.001 3 
No prophylaxis 62 (60.7%) 
Porru et al. 
D-mannose 12 (20%) P < 0.0001 2 
TMP-SMX 45 (75%) 
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reported symptom cure according to the Urinary Tract Infections Symptoms Assessment 
(UTISA). This was confirmed with urine culture. Cured subjects were then split into two groups 
for prophylaxis. Twenty-two subjects received D-mannose 1.5 g once a day for 1 week every 
other month for 6 months and 21 women received nothing. A statistically significant difference 
between the groups was observed. In the treatment group, 1 (4.5%) had a recurrence, while in the 
control group 7 (33.3%) had recurrence, P<0.05.6 This study showed a large treatment effect with 
NNT equal to 4. 
 Kranjcec et al. studied women who had acute cystitis and a history of recurrent UTI. 
Patients were considered to have an acute infection if they reported at least two irritative voiding 
symptoms. This was confirmed with a positive urine culture defined as >103 CFU in a clean-
catch specimen. Initial UTI was treated with ciprofloxacin 500 mg daily for 7 days and cure was 
defined as no lower urinary tract symptoms (LUTS) and <103 CFU on urine culture. Patients 
were then randomized to three groups and monitored for 6 months. The first group received 2 g 
D-mannose once daily at night. The second group was given nitrofurantoin 50 mg once daily at 
night. The third group was given nothing. If a patient reported LUTS during the follow-up 
period, she was said to have a recurrence, but urine culture was also performed.2 
In the D-mannose group, 15 (14.5%) reported recurrence. In the nitrofurantoin group, 21 
(20.3%) reported recurrence. In the group receiving no prophylaxis, 62 (60.7%) reported 
recurrence. The number of recurrent episodes was statistically different between the group with 
no prophylaxis and those with either D-mannose or nitrofurantoin (P< 0.001). Risk reduction 
(RR) of recurrent cystitis episode in the D-mannose group compared with the no prophylaxis 
group was 0.239 and was statistically significant (95% CI 0.146-0.392, P <0.0001). Risk 
reduction of nitrofurantoin and no prophylaxis was 0.335 and statistically significant (95% CI 
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0.222-0.506, P<0.0001). D-mannose showed a large treatment effect compared to no prophylaxis 
with NNT equal to 3. Importantly, this study shows a decreased risk of recurrence with D-
mannose than nitrofurantoin as reported in Table 3, but these two values may not be statistically 
different.2 
Table 3. Risk Reduction of Recurrent Cystitis D-mannose vs Nitrofurantoin 
Intervention RR 95% CI P-value 
D-mannose 0.239 0.146-0.392 P < 0.0001 
Nitrofurantoin 0.335 0.222-0.506 P < 0.0001 
 
 Porru et al. studied females with acute cystitis and a history of three or more documented 
UTIs in the last year. One group was treated with trimethoprim-sulfamethoxazole (TMP-SMX) 
160/800 mg twice a day for 5 days then once daily at night for one week of each month for 23 
weeks. The second group was treated with D-mannose 1 g three times a day for 2 weeks then 1 g 
twice daily for 22 weeks. At the end of the 24-week period, the subjects switched groups and 
were studied for an additional 24 weeks. Subjects were considered to have recurrence if new 
symptoms arose. In the D-mannose group, 12 (20%) had a UTI recurrence, while in the TMP-
SMX group, 45 (75%) had a recurrence. This study showed a large treatment effect with D-
mannose with NNT equal to 2. Under D-mannose mean TTR was 200 days (SD 50.7) and under 
TMP-SMX, mean TTR was 52.7 days (SD 11.2) and the difference was statistically significant 
(p<0.0001).7 Refer to Table 4. 
Table 4. Time to Recurrence of UTI TMP-SMX vs D-mannose 
Group Mean Time to 
Recurrence 
SD P-value 
D-mannose 200 days 50.7 P < 0.001 
TMP-SMX 52.7 days 11.2 
O’Leary, D-mannose and UTI Prophylaxis 8 
 
Secondarily, Porru et al. recorded patients’ descriptions of their pain and urgency on the 
visual analog scale (VAS). Prior to D-mannose treatment mean VAS pain was 4.4 (SD 1.1) and 
after treatment was 2.2 (SD 0.5). Mean VAS urgency before D-mannose was 4.6 (SD 1.1) and 
after was 2.6 (SD 0.7). These differences were statistically significant (p<0.001). Refer to Table 
5. VAS differences were not reported for the TMP-SMX group. However, this shows that D-
mannose not only prevents recurrence, but gives patients an improved sense of symptoms and 
irritation from recurrent infection. This is an important component for evaluating effectiveness of 
prophylactic therapy given the known psychologic distress caused by recurrent UTIs.7 
Table 5. VAS Pain and Urgency Before and After Treatment with D-mannose 
 VAS Pain VAS Urgency P-value 
Before Treatment 4.4 (SD 1.1) 4.6 (SD 1.1) P < 0.001 
After Treatment 2.2 (SD 0.5) 2.6 (SD 0.7) 
 
Adverse effects were reported by Krancjec et al. During the 6-month follow-up period, 
37 out of 206 patients (17.9%) reported side effects, but none were severe enough to warrant 
stopping therapy. In the D-mannose group, 8 patients (7.8%) reported diarrhea. No other side 
effects were reported in this group. In the nitrofurantoin group, 29 patients (28%) reported side 
effects. Of these, 10 reported diarrhea, 6 reported nausea, 3 headache, 1 skin rash, and 9 vaginal 
burning. See Table 6. Patients in the D-mannose group had a lower risk of side effects compared 
to nitrofurantoin and the difference was statistically different (RR 0.276, 95% CI 0.132-0.574, P 
< 0.0001).2 See Table 7. Domenici et al. had no reported side effects during treatment or 
prophylaxis with D-mannose.6 Porru et al. make no mention of adverse effects.7 
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Table 6. Number of Patients with Adverse Effects of Prophylaxis 
Adverse Effect D-mannose group (number 
of patients reporting) 
Nitrofurantoin (number of 
patients reporting) 
Diarrhea 8 10 
Nausea 0 6 
Headache 0 3 
Skin Rash 0 1 
Vaginal Burning 0 9 
 
Table 7. Risk reduction for side effects D-mannose compared to Nitrofurantoin 
RR 95% CI P-value 
0.276 0.132-0.574 P < 0.0001 
 
DISCUSSION 
 Recurrent urinary tract infections are a costly part of healthcare in the United States. In 
addition, these infections cause significant distress in affected women. Adequate prophylaxis 
measures that are both safe and effective are necessary to prevent continued recurrence of 
infection. Further, the advent of antibiotic resistance and the limited options for treating UTIs 
necessitate a safe and natural approach to preventing recurrent UTI. The primary objective of 
this systematic review was to evaluate the effectiveness of D-mannose as prophylaxis against 
UTI recurrence. Briefly explored, were patients’ impressions of their relief of common 
symptoms of UTI, and safety and tolerability of D-mannose.  
 Each of the studies had limitations that must be addressed. First, none of the studies were 
blinded. Domenici et al. and Krancjec et al. did not offer placebo to patients receiving no 
prophylaxis. Further, Porru et al. employed a crossover study that had different dosing regimens 
for the interventions used, making it easy to tell that the two treatments were different. 
Randomized, double-blinded studies should be pursued to better evaluate the effectiveness of D-
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mannose for prophylaxis against recurrent UTI. Further, each of the studies had relatively small 
patient populations. Studies involving more subjects with blinding should be conducted. 
An important limitation of Porru et al. is that trimethoprim-sulfamethoxazole (TMP-
SMX) was given less frequently and in lesser amount than D-mannose during the 24-week 
follow-up period. The study shows that D-mannose can effectively prevent recurrent urinary 
tract infection with only 20% of patients reporting recurrence with D-mannose. However, TMP-
SMX 160/800 was dosed once daily at night for one week each month for 6 months while D-
mannose was dosed 1 g twice daily. This inconsistency in dosing between the two agents limits 
the ability to regard one superior to the other. Recommendations for prophylactic regimens with 
TMP-SMX have not been concretely established, but empiric prophylaxis is most commonly 
low-dose TMP-SMX (80/400 or 40/200) nightly for 6 months.1 Dosing according to the current 
recommendation should be used for adequate comparison of the two agents.  
Another limitation is that all three studies used different doses of D-mannose for 
prophylaxis. Domenici et al. used 1.5 g nightly one week every other month for 6 months. 
Kranjcec et al. used 2 g nightly for 6 months, and Porru et al. used 1 g twice daily for 6 months. 
There has not yet been an established standard dose for D-mannose for prophylaxis of recurrent 
UTI but recommendations vary from 500 mg daily to 2 g daily in single or divided doses.2,8 
Further studies should be done to investigate optimal dosage.  
Regarding cost, D-mannose is an over-the-counter supplement that is not covered by 
insurance. However, it is an affordable over-the-counter alternative. To address tolerability, 
patients reported side effects that were minimal or absent in the studies, making this supplement 
safe and feasible for long-term use. Of note, while D-mannose is a sugar similar to glucose, it is 
not able to be converted to glycogen and therefore is not stored in the body.6 Long-term use of 
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this product, even in high concentrations, has shown no ill effects on metabolic function.6 Since 
this sugar has no effect on metabolism, its chronic use is of no concern for causing 
hyperglycemia, obesity, or metabolic disorders.8 Importantly, it can be considered safe in 
diabetic patients or those avoiding sugars for other reasons.8 
CONCLUSIONS 
 All three studies demonstrated that D-mannose is an effective prophylactic agent for 
recurrent UTIs in women who are prone to these infections. There was a significant difference 
between D-mannose and no agent for prophylaxis in two studies. D-mannose also showed a large 
treatment effect across all three studies. What cannot be determined from these studies is 
whether D-mannose is superior to nitrofurantoin or trimethoprim-sulfamethoxazole (TMP-SMX) 
in terms of efficacy. D-mannose shows similar efficacy to nitrofurantoin; however, it does 
appear superior in terms of safety and tolerability. Studies evaluating D-mannose compared to 
TMP-SMX using appropriate and comparable dosing of the two agents must be pursued. Further 
studies should investigate D-mannose for recurrent UTI prophylaxis in larger patient 
populations, and should seek to establish the most effective dosing regimen. Lastly, D-mannose 
does improve patient perception of symptoms as reported in one study, demonstrating that it may 
help decrease psychologic distress associated with recurrent UTI. Ultimately, D-mannose shows 
promise as an effective supplement that can prevent distressing recurrent UTIs, but it does 
require further study before becoming standard of care for all patients.
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